Celldex Therapeutics (CLDX) rallies the day after releasing favorable data from a Phase I/II...

Celldex Therapeutics (CLDX) rallies the day after releasing favorable data from a Phase I/II study for its cancer treatment DDX-1401. Celldex is testing the therapy for the treatment of such cancers as melanoma. CLDX +12.2% premarket. (PR)